BRIEF-Bristol-Myers says EMA validates type II variation application for Opdivo

* European Medicines Agency validates Bristol Myers Squibb's type II variation application for Opdivo (nivolumab) in advanced form of bladder cancer
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.